Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially accelerating cancer immunotherapy development.
Tevogen.AI to develop enhanced analytics and visualization tools, for the PredicTcell model to support its internal R&D teams.
WARREN, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) — Tevogen ('Tevogen Bio Holdings Inc.' or 'Company') (Nasdaq: TVGN) today announced that its artificial intelligence initiative, Tevogen.AI, is expanding its collaboration with Microsoft (Nasdaq: MSFT) and Databricks, to build the beta version of its foundational PredicTcell model.
Powered by the Databricks Data Intelligence Platform and backed by their innovative engineering teams, Tevogen.AI has begun curating a dataset focused on oncology. The dataset, aggregated with the initial virology dataset. aims to improve upon the accuracy of the alpha version of PredicTcell model.
This next phase of development builds on Tevogen.AI's recently published international patent application (WO 2025/129197), which outlines novel machine learning systems for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases.
'We have been extremely fortunate to work with such great organizations like Microsoft and Databricks to build the alpha version of our foundational AI model,' said Mittul Mehta, Chief Information Officer and Head of Tevogen.AI. 'Oncology represents one of the most impactful areas for AI in drug discovery, given the complexity of the disease and the limited availability of high-quality datasets.'
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen's plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as 'may,' 'could,' 'would,' 'expect,' 'anticipate,' 'possible,' 'potential,' 'goal,' 'opportunity,' 'project,' 'believe,' 'future,' and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio CommunicationsT: 1 877 TEVOGEN, Ext 701
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
PubMatic Inc (PUBM) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid DSP Challenges
Release Date: August 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points PubMatic Inc (NASDAQ:PUBM) reported a strong second quarter with revenue and adjusted EBITA ahead of expectations. Revenue from the underlying business, excluding DSP and political advertising, grew 19% year over year. CTV revenue grew over 50% year over year, indicating significant market share gains. Emerging revenue streams more than doubled year over year, accounting for 8% of total revenue. PubMatic Inc (NASDAQ:PUBM) has been actively diversifying its DSP mix, with newer DSPs growing at 20% plus rates. Negative Points Platform changes by a top DSP partner in July created revenue headwinds, impacting the second half of the year. The concentration of legacy DSP relationships is seen as a constraint on growth. There was a notable drop in spend from a top DSP in July, which stabilized in August but requires mitigation efforts. The company faces challenges due to limited visibility into DSP platform changes. Display revenues were flat year over year, indicating slower growth compared to other segments like CTV. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with PUBM. Q: Can you provide more details about the recent DSP changes and how they are impacting PubMatic's revenue? A: Rajeev Goel, CEO: In July, a top DSP buyer shifted a significant number of clients to a new platform that evaluates inventory differently, impacting our revenue. We are working to optimize the inventory we send to this DSP. The process will take several months, and we are accelerating our strategy to diversify ad spend away from legacy DSPs. Q: How is PubMatic addressing the DSP concentration risk, and what is the current concentration of DSPs? A: Steve Panttoli, CFO: Our top two DSPs represent about half of our overall spending. We are diversifying our DSP mix, with other DSPs growing their spend. For example, a commerce DSP is growing the fastest, and we have a new number 5 DSP. We are confident in our strategy to execute through this. Q: How are conversations with advertisers evolving, and how is this impacting your go-to-market approach? A: Rajeev Goel, CEO: Conversations are focusing on solving advertisers' challenges, such as transitioning away from cookies and towards identity-based targeting. We are investing in direct sales efforts and expanding into mid-market buyers, which may impact our SPO metric but will drive growth. Q: What is PubMatic's view on the evolution of the industry with the blurring lines between DSPs and SSPs? A: Rajeev Goel, CEO: The industry is moving towards end-to-end platforms, driven by shifts towards CTV, performance, and identity-based targeting. We are focusing on creating efficient paths for advertisers with Activate, providing transparency and control, and seeing significant traction in its growth. Q: How is PubMatic positioned to navigate the potential risks from generative AI to the display business? A: Rajeev Goel, CEO: Our exposure to AI search traffic is limited, with 60% of impressions from CTV and mobile apps, which are unaffected. We see an opportunity as AI search companies will likely need ad-supported business models, creating significant opportunities for us. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Fifth Third Bancorp Announces Earnings Release Dates for 2026 and 2027
CINCINNATI, August 12, 2025--(BUSINESS WIRE)--Fifth Third Bancorp (Nasdaq: FITB) is expected to report financial results and host conference calls to discuss results on the following dates: Fourth Quarter 2025 – Tuesday, January 20, 2026 – 10:00 AM ET First Quarter 2026 – Friday, April 17, 2026 – 9:00 AM ET Second Quarter 2026 – Friday, July 17, 2026 – 9:00 AM ET Third Quarter 2026 – Monday, October 19, 2026 – 9:00 AM ET Fourth Quarter 2026 – Tuesday, January 19, 2027 – 10:00 AM ET First Quarter 2027 – Tuesday, April 20, 2027 – 9:00 AM ET Second Quarter 2027 – Tuesday, July 20, 2027 – 9:00 AM ET Third Quarter 2027 – Tuesday, October 19, 2027 – 9:00 AM ET Financial results are expected to be available at approximately 6:30 AM ET on each of the dates listed above. Conference calls will be webcast live and may be accessed through the Fifth Third Investor Relations website at (click on "About Us" then "Investor Relations"). Those unable to listen to the live webcasts may access a webcast replay through the Fifth Third Investor Relations website at the same web address. About Fifth Third Fifth Third is a bank that's as long on innovation as it is on history. Since 1858, we've been helping individuals, families, businesses and communities grow through smart financial services that improve lives. Our list of firsts is extensive, and it's one that continues to expand as we explore the intersection of tech-driven innovation, dedicated people, and focused community impact. Fifth Third is one of the few U.S.-based banks to have been named among Ethisphere's World's Most Ethical Companies® for several years. With a commitment to taking care of our customers, employees, communities and shareholders, our goal is not only to be the nation's highest performing regional bank, but to be the bank people most value and trust. Fifth Third Bank, National Association is a federally chartered institution. Fifth Third Bancorp is the indirect parent company of Fifth Third Bank and its common stock is traded on the NASDAQ® Global Select Market under the symbol "FITB." Investor information and press releases can be viewed at Category: Earnings View source version on Contacts Matt Curoe (Investor Relations) | 513-534-2345Jennifer Hendricks Sullivan (Media Relations) | 614-744-7693
Yahoo
22 minutes ago
- Yahoo
Micron Rides AI Wave With Upgraded Outlook, Analysts See More Gains Ahead
Micron Technology (NASDAQ:MU) extended gains Tuesday after boosting its August-quarter outlook, fueled by surging demand and pricing for AI-focused memory chips, signaling continued momentum in the DRAM market through 2026. JP Morgan analyst Harlan Sur maintained Micron Technology (NASDAQ:MU) with an Overweight rating and raised the price forecast from $165 to $185 on Monday. Sur said Micron delivered a positive pre-announcement for its August quarter, raising revenue, gross margin, and EPS guidance on stronger-than-expected DRAM (or dynamic random access memory) pricing across AI/datacenter, smartphone, and PC now expects revenue of $11.2 billion versus its prior $10.70 billion midpoint, adjusted gross margin of 44.5% versus 42%, and adjusted EPS of $2.85 versus $2.50. Sur attributed the upside to sustained DRAM strength, improved DDR5 and LPDDR5 contract pricing, and robust HBM (or high-bandwidth memory) demand, with HBM revenue nearing an $8 billion annualized run rate. He highlighted that the HBM3e 12-Hi yield ramp exceeded the 8-Hi ramp and already reached crossover in volume, with visibility to sell out 2026 HBM supply, including HBM3e and HBM4. Tight supply in non-AI DRAM, partially driven by the HBM trade ratio, adds upward pricing pressure, while DDR4 end-of-life shortages contribute marginally. Sur expects DRAM pricing strength to continue through 2025 and into 2026, supported by substantial AI capex and constrained leading-edge supply from the HBM4 ramp. Citing solid execution, improving supply/demand fundamentals, and margin expansion potential, Sur raised his estimates and increased his price forecast from $165 to $185. His new forecast is based on $17 in annualized earnings power in second-half of 2026, applying a 10–12x P/E multiple consistent with mid-to-late cycle valuations for memory stocks. He maintained an Overweight rating, seeing Micron well-positioned for fiscal 2026 and calendar 2026, with strong momentum in high-margin businesses and market share gains. Price Action: MU stock is trading higher by 2.75% to $127.12 at last check on Tuesday. Image via Shutterstock Latest Ratings for MU Date Firm Action From To Feb 2022 Wedbush Upgrades Neutral Outperform Jan 2022 Goldman Sachs Maintains Buy Jan 2022 New Street Research Initiates Coverage On Buy View More Analyst Ratings for MU View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? MICRON TECHNOLOGY (MU): Free Stock Analysis Report This article Micron Rides AI Wave With Upgraded Outlook, Analysts See More Gains Ahead originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
